Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen.
Ke-Jun LiuHong-Rui LiQuan-Quan TanTao JiangKai-Cheng PengHua-Jun ChenQing ZhouXu-Chao ZhangZheng ZhengShi-Yuan ChenXue ZhengHong-Bo ZhengBei-Bei MaoLong-Long GongXian-Wen ChenWendy WuYi-Long WuJun JiaJin-Ji YangPublished in: Lung cancer (Amsterdam, Netherlands) (2024)
The immune microenvironment of EGFR ex20ins is more suppressive than that of L858R and wild-type, suggesting that ICI monotherapy may not be sufficient for these patients. ICI-combined regimen might be a treatment option for EGFR ex20ins due to tumor-promoting inflammation and noninferior T cell functions in the immune microenvironment.
Keyphrases
- small cell lung cancer
- epidermal growth factor receptor
- tyrosine kinase
- stem cells
- wild type
- end stage renal disease
- newly diagnosed
- ejection fraction
- oxidative stress
- chronic kidney disease
- prognostic factors
- combination therapy
- brain metastases
- randomized controlled trial
- peritoneal dialysis
- open label
- clinical trial
- patient reported
- smoking cessation